IKT-001

DRUG2 trials

Sponsors

Inhibikase Therapeutics

Conditions

Pulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH)

Phase 3

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

RecruitingNCT07365332

Inhibikase TherapeuticsPulmonary Arterial Hypertension

Start: 2026-04-23End: 2029-12-01Target: 486Updated: 2026-09-02

Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Not yet recruitingNCT07632898

Inhibikase TherapeuticsPulmonary Arterial Hypertension (PAH)

Start: 2026-10-23End: 2030-12-30Target: 484Updated: 2026-06-08